EpiBiologics Reports First Patient Dosed in P-I Study of EPI-326 for EGFR-Driven Solid Tumors

Shots: EpiBiologics has dosed the first patient in a global P-I study evaluating EPI-326, a tissue-selective bispecific antibody targeting EGFR, in advanced solid tumors The first-in-human study will assess safety, tolerability, PK, and preliminary anti-tumor activity in pts with NSCLC and HNSCC, with potential expansion into colorectal cancer Preclinical data showed robust anti-tumor activity across…

ByPrince GiriApril 20, 2026

Kymera Therapeutics Reports Gilead’s Option Exercise to License KT-200, a CDK2 Molecular Glue Degrader

Shots: Gilead Sciences has exercised its option to exclusively license KT-200, a first-in-class oral CDK2 molecular glue degrader, from Kymera Therapeutics under their existing collaboration The option exercise triggers a $45M milestone payment to Kymera; the company remains eligible for up to $750M in total payments, including milestones and tiered royalties on net sales Gilead…

ByPrince GiriApril 10, 2026

Enodia Acquires Kezar’s Sec61 Program to Advance Targeted Protein Degradation Pipeline

Shots: Enodia has acquired Kezar’s Sec61-based discovery & development program assets, strengthening its understanding of Sec61 selectivity mechanisms & expanding translational insights to accelerate progress toward key clinical milestones As per the deal, Kezar will receive a $1M upfront, ~$127M in development, regulatory, & commercial milestones, plus tiered royalties on future net sales Enodia’s platform…

ByRidhi RastogiMarch 13, 2026

EpiBiologics Reports First Patient Dosed in P-I Study of EPI-326 for EGFR-Driven Solid Tumors

Kymera Therapeutics Reports Gilead’s Option Exercise to License KT-200, a CDK2 Molecular Glue Degrader

Enodia Acquires Kezar’s Sec61 Program to Advance Targeted Protein Degradation Pipeline

Contact US

FOLLOW US